GON Stock Chart & Stats
CHF1.22
--
Market closed
CHF1.22
--
Day’s Range― - ―
52-Week RangeCHF1.06 - CHF1.30
Previous CloseN/A
VolumeN/A
Average Volume (3M)71.00
Market Cap
CHF694.80M
Enterprise ValueCHF807.52
Total Cash (Recent Filing)CHF300.85M
Total Debt (Recent Filing)CHF122.14M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Nov 11, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding642,473,400
10 Day Avg. Volume0
30 Day Avg. Volume71
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF3.55Price Target Upside191.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)CHF192.35M
Bulls Say, Bears Say
Bulls Say
RYTELO Revenue GrowthSustained product revenue growth indicates expanding adoption of RYTELO and provides a developing commercial foundation. Continued account expansion and management’s maintained guidance support the potential for a broader recurring revenue base over the next several quarters.
Commercial Footprint ExpansionGrowth in prescribing accounts and demand suggests Geron’s commercial strategy is gaining traction beyond an initial launch cohort. A broader provider footprint can improve patient identification, support repeat utilization, and strengthen the product’s market position over time.
Improved Capital StructureThe sharp reduction in leverage gives Geron greater financial flexibility than it had in the prior year. Lower debt obligations can reduce balance-sheet pressure and leave more capacity to fund commercialization and clinical development while the company scales.
Bears Say
Persistent Cash BurnDeeply negative operating and free cash flow show that the current commercial business is not yet self-funding. Continued burn may require external financing or balance-sheet resources, creating longer-term dilution and execution risk if profitability is delayed.
Ongoing Net LossesGeron remains materially unprofitable despite improved revenue and narrower operating losses. Persistent net losses limit internally generated capital and make future earnings dependent on successful scaling, disciplined spending, and continued growth in product economics.
Higher Gross-to-net DeductionsRising gross-to-net deductions reduce realized revenue per unit and can constrain the economic benefit of prescription growth. If the elevated range persists, Geron may need greater volume or cost discipline to convert commercial momentum into sustainable margins.
Geron News
GON FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was CHF1.06 and its highest was CHF1.30 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is CHF694.80M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 11, 2026 which is in 55 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 05, 2026. The company reported -CHF0.016 earnings per share for the quarter, missing the consensus estimate of -CHF0.007 by -CHF0.009.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp does not currently pay dividends.
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corp have?
Geron Corp has 642,473,400 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -CHF0.016 in its last earnings report, missing expectations of -CHF0.007. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in CH:GON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF3.55 (191.10% Upside)
CHF3.55 (191.10% Upside)
Blogger Sentiment
Bullish
CH:GON Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Geron Corp
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GON Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.View all CH:GON earnings summariesGON Stock 12 Month Forecast
Average Price Target
CHF3.55
▲(191.10% Upside)